EU panel backs approval of GSK's cancer drugs Tafinlar and Tyverb

07/2/2013 | Pharmaceutical Business Review Online

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of GlaxoSmithKline's Tafinlar, or dabrafenib, as a treatment for unresectable or metastatic melanoma in patients with the BRAF V600 mutation. GSK's Tyverb, or lapatinib, along with trastuzumab, was also recommended for approval as combination therapy for certain breast cancer patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY